Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients
ABSTRACT
Background: The aim of the study is to determine the prognostic relevance of CD200/ CD56
expression in adult acute lymphoblastic leukemia patients.
Methods: The expression of CD200 and CD56 by blast cells was assessed by flow cytometry
before the start of chemotherapy in 70 B-ALL patients.
Results: Positive expression of CD200 was detected in forty-six patients (66%) and CD56 was
detected in 7 patients (10%) out of 70 patients, respectively. Only three patients (4.3%) had
co-expression for CD200+ and CD56+. Splenomegaly and thrombocytopenia were frequently
observed more in CD200+ patients. Increased frequency of CD34+ was associated with
CD200+and CD56+ patients. The CD200+ and CD56+ subgroups of B-ALL patients had inferior
OS and disease free survival compared to CD 200− and CD 56− patients.
Conclusions: CD200+ and/or CD56+ positive expression in B-ALL patients at diagnosis is a poor
prognostic biomarker. Identification of CD200+ and CD56+ expression at diagnosis is
recommended for a better stratification of adult B-ALL patients.